Mead Johnson & Company

Bristol-myers Squibb Compnay

Joseph A Scott

Robert J Bequette

Robert L Alexander

Terry T Kensler

Robert J Behme

Dana Brooke

Linda G Hobbs

A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

Lyophilized cyclophosphamide

Improved lyophilizate compositions of ifosfamide comprising urea as the primary excipient and, optionally, mesna, are produced in a modified freeze-drying process to give products with increased heat stability and extended shelf storage life.

Lyophilized ifosfamide compositions

Loss of potency of estradiol cream compositions found to be due to unexpected oxidation of estradiol. Improved cream composition comprises 1% or less 17.beta.-estradiol in the presence of stabilizing members selected from phenolic-type antioxidants, metal chelating agents, and suspending agents.

Stabilized estradiol cream composition

Growing community of inventors

Evansville, IN, United States of America

Joseph A Scott